Megakaryocyte Growth and Development Factor Accelerates Platelet Recovery in Peripheral Blood Progenitor Cell Transplant Recipients
We have investigated the potential of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a molecule related to thrombopoietin (mpl ligand or TPO) in minimizing the thrombocytopenia associated with hematopoietic ablation and peripheral blood progenitor cell (PBPC) transplant. Irradiated mice that received PBPC mobilized by PEG-rHuMGDF or granulocyte colonystimulating factor (G-CSF) had a reduced number of thrombocytopenic days with platelets below 100 x 10' per mL of blood. Recipients of unmobilized PBPC had a 9 day thrombocytopenic phase which was shortened to 7 days if they were given granulocyte-macrophage colony-stimulating factor (GM-CSFj-mobilized PBPC. This was further reduced to 2 or 3 days of thrombocytopenia in recipients of G-CSF-or PEG-MGDF-mobilized PBPC. Despite our observation that PEGrHuMGDF is a relatively modest stimulator of the mobilization of myeloid progenitors to the blood, MGDF-mobilized PBPC do effect accelerated recovery of platelets after trans-ERIPHERAL BLOOD progenitor cell (PBPC) harvests P are replacing bone marrow (BM) as the tissue of choice for hematopoietic support of ablated patients and for improving the rate of hematopoietic recovery in myelosuppressed patients.'-6 PBPC are normally present in very low numbers in the blood so large volumes of blood need to be processed to obtain sufficient cells for engraftment.7,8 Hematopoietic growth factors (HGF) can substantially increase the number of PBPC collected at each round of leukapheresis9-" and harvests from HGF-treated patients have been shown to outperform conventional BM grafts in terms of the rate of recovery of PB population^.'^-'^ PBPC are also at least equivalent to BM in terms of the ability to sustain stable long-term engraftment.16'17 The ease of collection together with the advantages outlined above make HGF mobilized PBPC preferable to BM in many situations.
The usefulness of HGFs has also been shown in the posttransplant setting where blood cell recovery rates can be improved by treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage CSF (GM-CSF) in the period after transplantation.','*-'' Traditionally the improvement of platelet recovery has proven more refractory to growth factor therapy, and though clinical studies have indicated that G-CSF mobilized PBPC can sustain accelerated platelet recovery in patients,' a concern remained that the potential of PBPC may not be fully exploited in trans-plantation. However, the most effective use of PEGrHuMGDF is when it is given during the recovery phase after PBPC transplantation to hematopoietically ablated mice. Posttransplant treatment with PEG-rHuMGDF reduces thrombocytopenia to a single day or less, in recipients of most types of PBPC. Mice that were treated during the first 2 weeks after PBPC transplant with PEG-rHuMGDF had 1 thrombocytopenic day compared to 9 days in carrier-treated recipients of unmobilized PBPC and 2 to 3 days in carriertreated recipients of the optimally mobilized PBPC from G-CSF or G-CSF/PEG-rHuMGDF treated donors. In groups where PEG-rHuMGDF was included in the mobilization protocol and used to treat recipients as well thrombocytopenia was effectively eliminated. These data show that PEGrHuMGDF is a highly effective agent in eliminating the thrombocytopenia associated with PBPC transplantation. plant recipients lacking the support of an effective thrombopoietin (TPO).
The recent cloning of the mpl ligand (also called TP0,22-2h) has raised the possibility of artificially stimulating accelerated recovery of platelets in various settings including myeloablated recipients of hematopoietic cell grafts. Megakaryocyte growth and development factor (MGDF), a molecule related to TPO, may also have potential as a hematopoietic cell mobilizer in PBPC donors.
The experiments described here were designed to address several potential uses of MGDF treatment. Firstly, by treating PBPC donors we determined whether PEG-rHuMGDF could increase the number of PBPC available for harvest. Secondly, by combining PEG-rHuMGDF treatment with either G-CSF or GM-CSF we attempted to modulate the quality of the product obtained in terms of its subsequent performance in transplant recipients. Thirdly, we undertook treatment of PBPC recipients with PEG-rHuMGDF to attempt to improve platelet recovery above even that obtained with CSF-mobilized PBPC. And finally, we combined PEGrHuMGDF treatment of the PBPC donor with PEGrHuMGDF treatment of the recipient. In this setting we attempted to both improve the quality of the graft and maximize the exploitation of any improvement by treating the recipient with an effective TPO.
Our data show the usefulness of PEG-rHuMGDF in the posttransplant setting and PEG-rHuMGDF presents us with the possibility of maximizing platelet recovery in recipients of PBPC mobilized by HGF as well as in idiopathic and chemotherapy-associated thrombocytopenic conditions.
MATERIALS AND METHODS

Mice
Splenectomized male C5,B1 X DBAz (BDF,) DBF, mice 12 to 20 weeks of age were used as donors and female BDF, mice 8 to 12 weeks of age were used as transplant recipients. Preparative irradiation was 1, 200 cGy (I3'Cs, dose rate 106.7 cGy/min) given as a split dose of 2 x 600 cGy, 4 hours apart. All transplant experiments were repeated three times.
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Donor Treatment
Mice were implanted with Alzet Micro-osmotic (1007D) pumps ( A l a Corp, Palo Alto, CA). The pump, which was handled and filled under aseptic conditions, was inserted subcutaneously through a small incision made through the skin between the scapulae of anesthetized (Aerrane, Ohmeda Carbide Inc, Guayama PR) mice. Seven days later mice were killed by carbon dioxide inhalation and blood withdrawn via cardiac puncture. This blood was collected in evacuated glass tubes containing 50 pL 15% EDTA (Vacutainer 6536; Becton Dickinson, Rutherford, NJ). Between 800 and 1,200 pL was collected from each donor, typically groups of 10 donors were used. Complete blood counts were performed on individual blood samples on a Technicon H-IE (Technicon Instruments Corp, Tarrytown, NY) calibrated for the analysis of mouse blood. Blood from individual donors was assayed for GM-CFC content. Five hundred microliters of blood from each donor in a treatment group was then pooled and diluted to 6 mL with carrier and carefully layered over a 25 mL cushion of density separation medium (Accudenz, Accurate Chemical and Scientific Corp, Westbury, NY). After centrifuging at 8008 for 20 minutes, buoyant density cells were collected, washed 2 times, counted on a Technicon H-I E, the count was confirmed manually with a hemocytometer and cells were resuspended at 4 X 10' white blood cell (WBC)/mL.
Recipient Treatment
Twenty-four hours before irradiation recipient mice were implanted with Alzet 2002 mini-osmotic pumps containing dilutions of PEG-rHuMGDF, which corresponded to a calculated delivered dose of 50 jig PEG-rHuMGDFlkg body weight/d or the equivalent volume of carrier solution (phosphate-buffered saline [PBS], Life Technologies, Grand Island, NJ) supplemented with 0.1 % bovine serum albumin ([BSAIIPBS, Sigma, St Louis, MO), which was also used to dilute growth factors for infusion. After irradiation these mice were injected intravenously with 500 p L of the cell suspension previously described containing 2 X IO" PB cells from donors that had been variously treated. Groups of IO recipients were divided into two groups of five and blood was withdrawn from the retroorbital sinus of anesthetized animals via heparinized glass capillaries into tubes containing 10 pL 3% EDTA. This blood was analyzed on a Technicon H-IE. Blood samples were collected from either group of 5 mice alternately, thus one cohort of 5 mice was sampled on days 5, 9, 12, 16, and 21, and the other cohort on days 7, 10, 14, and 19 after transplant. Transplant experiments were repeated three times. Mononuclear cell (MNC) preparations from groups of 5 to 20 donor mice were injected into groups of 10 recipient mice that were divided as outlined above. In total 270 donor and more than 350 recipient mice were used.
Growth Factors
Recombinant human MGDF is a molecule related to a truncated form of TPO, which is expressed in Escherichia coli" and PEGylated. All growth factors were prepared at appropriate dilutions to give the dose levels indicated in the Results section. A dose of 200 pg/kg/d of rhG-CSF was used in comparison with a dose 200 pg/ kg/d rmGM-CSF and PEG-rHuMGDF at 50 pg/kg/d. Treatment was administered by continuous subcutaneous infusion via Alzet miniosmotic pumps. Delivery from these pumps could be expected to begin within 4 hours and continue for up to 18 days. Carrier solution was PBSBSA and was used to dilute growth factors for infusion, or given alone to carrier-treated animals.
Colony-Forming Assay
Aliquots of between 5 and 50 pL of whole blood were removed from individual blood samples obtained as previously described. This volume was added to 3 mL of plating mix. Aliquots of 1 mL were then immobilized with 0.33% agar noble (Difco, Detroit, MI) in triplicate Falcon 35 mm petri dishes (Becton Dickinson, Lincoln Park, NJ) in the presence of Iscoves Modified Dulbecco's Medium (Life Technologies) supplemented with 20% preselected fetal bovine serum (Cansera, Rexdale. Ontario, Canada), 20 ng/mL rrSCF (Amgen, Thousand Oaks, CA) and 2.5 ng/mL rmIL-3 (Amgen). Cultures were maintained at 37°C for 7 days in fully humidified N2 plus 5% O2 and 5% C02. Remaining erythrocytes in the plates were lysed at the end of the culture period by careful addition of 300 pL 0.3% acetic acid to the surface of the gel and colonies of greater than 50 cells were counted under a dissecting microscope.
Statistical Analysis
Treatment groups (typically 5 independent mice from each of 3 experiments, ie, 15 mice per point) were compared with Student's t-test using Sigmastat (Jandel Scientific, San Rafael, CA) statistical software running in an IBM PC compatible computer.
RESULTS
Analysis of PBPC Donors
Implantation sites in mice were inspected regularly. All donor mice were healthy and had pumps still in position and in good condition at the end of the mobilization protocol. Recipients of rHuPEG-MGDF showed increased numbers of platelets. At the 7 day time point shown in Fig 1, levels of over 4,700 X lo6 platelets/mL, around 3.5 fold more than for carrier-treated mice, were noted in PEG-rHuMGDF treated mice. Platelet volume was increased from 5.4 t 0.19 f L in normals to 5.9 -C 0.17 fL. WBC, neutrophils, and monocytes were increased by a relatively small amount in PEG-rHuMGDF treated donors and red blood cell (RBC) numbers were unchanged.
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From Predictably, G-CSF and GM-CSF increased the numbers of circulating WBC from 21.8 X 106/mL in carrier-treated mice to 93.1 2 21 X lo6 and 44.2 ? 15.3 X 106/mL, respectively. This was accounted for almost entirely by an 18-fold increase in neutrophils and an 11 -fold increase in monocytes in G-CSF treated mice and fivefold increases in both populations in GM-CSF recipients. Platelets numbers were reduced by 34% in G-CSF and 54% in GM-CSF treated recipients.
Mean platelet volume was increased to 5.78 2 0.12 fL in G-CSF treated mice, but was slightly subnormal at 5.34 2 0.16 fL in GM-CSF treated mice. Mice which received PEGrHuMGDF in addition to G-CSF or GM-CSF showed some interesting modifications to the CSF-only response. G-CSF/ PEG-MGDF mice had similar numbers of WBC, neutrophils and monocytes to mice treated with G-CSF alone. Interestingly, the reduction in platelet numbers seen in G-CSF mice was completely reversed in recipients of the combination. A more modest correction was noted in GM-CSFPEGrHuMGDF mice where the magnitude of the WBC, neutrophil, and monocyte response was unchanged from the GM-CSF alone mice but in these animals platelet number was only partially corrected (see Table 1 ). Platelet number and mean platelet volume, which appeared slightly low in GM-CSF treated mice were comparable to control in recipients of GM-CSF when it was combined with PEG-rHuMGDF ( Table 1) .
GM-CFC Progenitor Numbers
PEG-rHuMGDF had very little influence on the number of circulating GM-CFC, see Table 2 . Both G-CSF and GM-CSF increased substantially both the concentration (in terms of GM-CFC per million cells) and absolute number of progenitor cells in the blood. Administration of either of the CSF' s in combination with PEG-rHuMGDF increased slightly the number of progenitors, and had little effect on their concentration. GM-CSF was slightly inferior to G-CSF in terms of the mobilization effect, an effect accounted for largely by the reduced degree of leukocytosis induced by GM-CSF in comparison to G-CSF (Table 3) .
Analysis of Harvest and Grafi
Blood was harvested from the treated donors via cardiac puncture. An equal volume of blood from each donor was pooled and calculations made of the number of cells in each pooled sample. The results of these calculations are shown in Table 3 . The blood was then carefully layered over density separation medium (Accudenz), centrifuged, washed and a buoyant density MNC fraction prepared. A summary of the cellular analysis of the preparations obtained is shown in Table 3 . The lymphocyte population probably also includes progenitor cells. Some of these cells were measured functionally in the GM-CFC assay. The number of progenitor cells may not have been substantive enough to account for a significant proportion of the "lymphocyte" window. However, progenitor cells (of many lineages) were undoubtedly present. On the purely physical parameters employed by the blood cell analyzer used for these studies they could not be separated from the lymphoid populations. The MNC preparation was diluted to allow the transplantation of a standard number of 2 X IO6 WBC to be given to each recipient. The precise composition of the graft is shown in Table 3 . The number of progenitor cells transferred has been calculated from the input number and the recovery of MNC assuming 100% recovery of progenitors in all groups.
The preparative procedure enriched for mononuclear cells to over 85% in all groups. The lowest purity was obtained in groups which received G-CSF and resulted mainly from neutrophil and monocyte contamination of the product. Preparations from GM-CSF treated donors had less contamination with neutrophils, but then the degree of leukocytosis induced in the treated mice was relatively modest compared to G-CSF.
Analysis of PBPC Recipients
Results are presented from the recovery period between transplant (day 0) and up to 21 days later. Presented data For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From are limited to recovery of WBC and platelets since these parameters reflect the major clinical concerns, which can be addressed by this type of experiment. Recipient mice were treated in two ways. For 1 day before transplant and for 16 days after transplant, the mice were exposed continuously to either carrier, or to PEG-rHuMGDF at 50 pg/kg/d delivered by osmotic pumps implanted 1 day before irradiation and transplantation. Baseline recovery is shown in Fig 2A, B , and C. The duration of leukopenia, taken as the number of days below 1 x lo6 WBC/mL and the period of thrombocytopenia, taken as days below 100 X lo6 platelets/mL, are shown in Table 4 . All mice received a graft of PBPC from either normal donors or from mice treated with various mobilizing regimens. Treatment of the PBPC donor with G-CSF effected accelerated WBC recovery. Figure 2A shows that PEG-rHuMGDF mobilized PBPC also accelerated slightly the recovery of WBC in subsequent transplant recipients. Treatment with a combination of both factors resulted in approximately additive improvement in WBC recovery. PEG-rHuMGDF-PBPC also lead to accelerated platelet recovery though the improvement was much less than was seen in recipients of G-CSF mobilized PBPC. ComCarrier-treated recipients.
bination G-CSFPEG-rHuMGDF mobilized PBPC performed equally with G-CSF mobilized PBPC, with perhaps a small advantage towards the end of the study period. GM-CSF was also capable of mobilizing PBPC (Fig 2B) that caused accelerated recovery of both WBC and platelets in transplant recipients, but the magnitude of the effect was much more modest than that seen with G-CSF donor treatment. PEG-rHuMGDF had an effect of similar magnitude to GM-CSF when given to donors to mobilize PBPC, and again an approximately additive effect was seen in combination treated donors. A direct comparison between mobilization between the two CSFs is presented in Fig 2C. These are the same data as shown in Fig 2A and 2B , but regrouped to allow a direct comparison to be made. G-CSF was the more effective mobilizer whether WBC or platelet recovery in the recipients was considered as the evaluable endpoint.
In general, the recovery of both WBC and platelets was faster and occurred sooner in recipient mice treated with PEG-rHuMGDF compared to carrier treated recipients. engrafted with PBPC from carrier-treated donors. PEGrHuMGDF mobilized PBPC performed comparably to nonmobilized PBPC when the recipients also received PEGrHuMGDF (Fig 3A) . The accelerated platelet recovery obtained with G-CSF mobilized PBPC (Fig 2A) was duplicated or exceeded in recipients of nonmobilized PBPC when the recipients were treated with PEG-rHuMGDF. However, a slight advantage in WBC recovery (between days 9 and dlffer significantly from either GM-CSF curve betwaon days 9 and 14 (P < .01). On the p1.td.t curves dinerenoes between G-CSF curves and GM-CSF curves ara significant on days 9 through 16 (P < .01).
14) was still obtained by treating the donor with G-CSF to mobilize PBPC. PBPC mobilized by combination G-CSF/ PEG-rHuMGDF showed comparable recovery to other treatment groups in terms of WBC recovery (Fig 3C) . Platelet recovery in all groups was faster and occurred with little or no delay in all recipients that received PEG-rHuMGDF in addition to the PBPC graft. The exception to this was PBPC derived from GM-CSF treated donors (Fig 3D) . This deleteFor personal use only. on August 30, 2017 . by guest www.bloodjournal.org From G-CSF rious effect of GM-CSF in the mobilization protocol could be ameliorated by inclusion of PEG-rHuMGDF in the donor treatment ( Fig 3E) . Figure 3F shows a direct comparison between the performance of G-CSF and GM-CSF PBPC mobilization products in PEG-rHuMGDF treated recipients. GM-CSF-mobilized PBPC performed much more poorly than G-CSF-or PEG-rHuMGDF-mobilized PBPC, or indeed nonmobilized (carrier treated donor) PBPC. This effect could be removed or minimized by treating the PBPC donor with PEG-rHuMGDF (Fig 2B and C) or the recipient ( Fig  3E and F) .
DISCUSSION
Administration of PEG-rHuMGDF to PBPC recipients markedly enhanced platelet recovery. In some cases thrombocytopenia, defined here as fewer than 100 X lo6 platelets per mL, was completely eliminated. This finding points to a major clinical application of PEG-rHuMGDF. These data show PEG-rHuMGDF to be the most potent thrombopoietic agent reported to date. Though studied in entirely different settings the effects of IL-3,27-29 IL-6,30"2 PEGylated-IL-6,33 PIXY32134 and IL-1135-38 are minimal by comparison. In keeping with the results reported in normal mice22,23.26 and in our donor mice in this study, transplanted mice treated with PEG-rHuMGDF were all healthy with no apparent side effects in any treatment group.
The PB analyses of the PBPC donor mice indicate (Fig  1) that PEG-rHuMGDF had no effect on nucleated white cell counts, but increased platelet counts from around 1,300 X lo6 mL in controls to more than 4,500 X lo6 mL in PEGrHuMGDF treated mice. G-CSF and GM-CSF, on the other hand, increased WBC from around 20 X 106/mL (which is normal in these older splenectomized mice) to about 100 and 40 X lo6 WBC/mL respectively. Thus, though these two factors were administered at equivalent doses (200 pgkgld) the degree of leukocytosis induced was quite different. The G-CSF appeared, gram for gram, to be about twice as potent as the GM-CSF. Despite this, the reduction in platelet numbers to around 800 X lo6 mL in these mice was broadly equivalent. In donors that received the combination treatments this slight reduction in platelet numbers was fully reversed in G-CSFPEG-MGDF recipients but remained slightly subnormal in GM-CSFPEG-MGDF recipients. In further experiments where the dose of G-CSF was reduced to 40 to 70 pgkgld a similar degree of leukocytosis was induced as in recipients of 200 pg GM-CSFkgld. In these lower dose G-CSF-treated mice platelet numbers remained normal. Therefore, it was unclear what doses of the two CSFs were directly comparable in terms of biological response and so the majority of our studies used doses of 200 pgkgld for each of the CSFs without further consideration of the leukocytosis-inducing activity of the material.
Both G-CSF and GM-CSF were effective mobilizers of potentially transplantable hematopoietic progenitors and one of our aims here was to evaluate PEG-rHuMGDF in this setting also. It was found that PEG-rHuMGDF was not an effective mobilizer in comparison with G-or GM-CSF, but was about as effective as some other reported materials such as MIP-la3' As a measure of mobilization of PBPC we used an assay of progenitor colony formation in the presence of rrSCF and rmIL-3. The progenitor population identified in this plating system may not be representative of the mobilization of so-called stem cells. It is possibly unrepresentative of megakaryocytic progenitor numbers also. However, it is apparent from several studies, including those of McNiece et ala that progenitor numbers of any functional type (including CFU-Meg) are equally predictive of patient platelet recovery. The studies of McNiece et al4 and clinical experience first illustrated by Sheridan et a12 indicate that G-CSF is a potent mobilizer of multiple progenitor types including megakaryocyte progenitors. It is possible of course that the mobilization of committed platelet progenitors occurs as an inadvertent side effect of myeloid progenitor mobilization by G-CSF. It is also a possibility that among the PBPC population harvested from G-CSF treated patients is a precursor population common to both lineages. Whichever hap- 
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ing the potential of the PBPC graft was the next area we investigated.
From the effects of PEG-rHuMGDF in normal mice it was predictable that an effect on platelet recovery rate might be expected in irradiated, transplanted mice treated with PEG-rHuMGDF. This proved to be the case, but the degree of the effect was greater than we had predicted. eloid progenitors and so it was reasoned that the observed effects may well be indirect. We also observed (though data are not presented) that recovery of erythrocyte numbers is improved in PEG-rHuMGDF treated PBPC recipients. It is unclear whether either of these effects are mediated via a direct effect of PEG-rHuMGDF on the populations in question. Several recent publications have indicated a role for some TPOs as cofactors in the growth of erythroid progenitor ~ells,4'.~* and shown erythropoietic effects in some models of myelos~ppression~~ or BMT donor treatment.43 Thus we cannot eliminate the possibility that PEG-rHuMGDF may have a direct beneficial effect on erythropoiesis, despite the lack of evidence to this effect in normal rodent^'^,*^ or primates.44 An intriguing possibility exists that platelets may influence myeloid and/or erythroid recovery via the effects of platelet derived materials on the functional recovery of other tissues including the hematopoietic microenvironment. It has been widely documented that cells grown in vitro, which have a functional role in the marrow stroma can be influenced by platelet derived factors such as PDGF. It is not clear which of these or other candidate mechanisms may play a part in the PEG-rHuMGDF supported recovery of either leukocytes or erythrocytes, but it is clear that recovery of either population is certainly not suppressed in animals receiving highly effective doses of PEG-rHuMGDF confounding any concern over possible interlineage competition between the thrombopoietic and myeloid lineages which may have been inferred from data obtained in normal mice.
Previous experience with mouse models of hematopoietic transplantation have proven generally predictive of the response obtained in the clinic. Despite this it is always a concern that rodent data may not be readily extrapolated to the clinical setting. For instance, in our experience the advantages of PBPC grafting over marrow transplantation in terms of myeloid cell recovery rates are not easily reproduced in mice, though they have been widely reported in the clinic. This may be the result of the differing ablation regimes employed or because of intrinsic differences between species. Nevertheless, comparisons between various rodent mobilization regimens have proven generally applicable to humans and the advantages of HGF (especially G-CSF) mobilized PBPC over harvests from carrier-treated donor blood have been shown again in these studies. However, the effects of recipient treatment with PEG-rHuMGDF are of sufficient magnitude that even unmobilized PBPC perform remarkably well. So does mobilization of PBPC in the donor still offer any advantage? Undoubtedly the answer is yes because there is considerable benefit to be gained from transplanting HGF-mobilized PBPC whether the recipient receives PEG-rHuMGDF posttransplant or not. Firstly, preliminary experiments have shown that recipients of optimally mobilized PBPC enjoy a considerable survival advantage over recipients of nonmobilized PBPC. Secondly, irradiated mice that receive no graft but are treated with PEGrHuMGDF show improved platelet recovery, but no parallel increase in survival rate. This infers that at least some graft is required and studies such as those previously discussed4' show that quantitatively, HGF mobilized PBPC are superior to other sources. The use of PEG-rHuMGDF treatment in the posttransplant period either alone or with agents such as G-CSF, may allow the minimum number of PBPC required for engraftment to be reduced, raising the possibility of splitting a pheresis product for multiple treatments over successive rounds of therapy, using nonexpanded cord blood as a viable tissue source in adults, and also of engrafting with the limited cell numbers attainable with current fluorescenceactivated cell sorting and gene therapy protocols.
Overall we have shown the efficacy of PEG-rHuMGDF in hematopoietic transplantation and conclude that this may be a significant potential application for this novel therapeutic.
